OncRef

Clinical Trial: NCT02608216

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:University of Pennsylvania
Information Provided By:University of Pennsylvania
Last Update Posted:2026-10-07

Study Overview

Brief Summary

In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer [18F]fluorothymidine (FLT).

Official Title

[18F]Fluorothymidine (FLT) PET/CT Imaging in Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 and Weekly Paclitaxel Therapy

Conditions

Breast Neoplasm, Metastatic Breast Cancer, Rb+ Breast Cancer

Intervention / Treatment

  • Drug: [18F]FLT
  • Device: PET/CT
  • Drug: ribociclib
  • Drug: paclitaxel

Other Study ID Numbers

  • 822997

Start Date

2015-11

Primary Completion Date (Estimated)

2026-11

Study Completion Date (Estimated)

2026-11

Enrollment (Estimated)

20

Study Type

Interventional

Phase

Phase 1